Aerska is a technology company.
Aerska has raised $60.0M across 2 funding rounds.
Aerska has raised $60.0M in total across 2 funding rounds.
Aerska has raised $60.0M in total across 2 funding rounds.
Aerska's investors include age1, LSP Dementia Fund, Iaso Ventures, Backed VC, Seed Club Ventures.
Aerska is a biotechnology company developing RNA interference (RNAi) medicines to treat, delay, and prevent brain diseases, primarily targeting genetic forms of Alzheimer’s and Parkinson’s. It serves patients with neurological disorders by solving the critical challenge of delivering genetic therapies across the blood-brain barrier using an antibody-oligo conjugate (AOC) platform with "brain shuttles" for systemic administration, neuronal uptake, and durable gene silencing.[1][2][3] The company launched in 2025 with $21 million (€17.8-18 million) in seed financing co-led by Age1, Backed VC, and Speedinvest, plus investors like Blueyard, Lingotto, Norrsken VC, and Ada Ventures, fueling platform development, data science for precision medicine, and an initial pipeline focus.[2][3][4][6] Headquartered in Dublin, Ireland, with research in London, UK, Aerska shows strong early momentum through expert founders and investor backing amid rising demand for CNS therapeutics.[1][2]
Aerska emerged in 2025 from the vision of CEO and co-founder Jack O’Meara, former CEO of Ochre Bio where he advanced RNAi medicines for liver disease and secured over $1 billion in pharma partnerships.[1][3][4] He teamed with co-founder Stuart Milstein, who led brain delivery at RNAi pioneer Alnylam Pharmaceuticals and now serves as CSO at Orfonyx Bio, plus research head Mike Perkinton, ex-executive director at AstraZeneca’s neuroscience division.[1][3] The idea crystallized around overcoming RNAi’s liver success limitations by innovating brain delivery via shuttles, inspired by the Gaelic proverb on collective strength—fitting for their collaborative push against the blood-brain barrier.[2][3] Early traction came via $21 million seed funding announced October 2025, validating their platform and precision medicine strategy with data science investments.[2][4][6]
Aerska rides the RNAi therapeutics wave, building on liver successes (e.g., Alnylam) to unlock CNS potential amid surging neurological disease burdens—Alzheimer’s and Parkinson’s affect millions, with few disease-modifying options.[1][2][4] Timing aligns with advances in brain shuttles and precision medicine, fueled by aging populations (centenarians projected to multiply) and a shift to preventative neurology over reactive care.[3][4] Market forces like Big Pharma’s neuroscience investments and data-driven patient stratification favor Aerska, positioning it to influence the ecosystem by pioneering scalable genetic CNS therapies and inspiring similar barrier-breaking biotechs.[1][2]
Aerska is primed to advance its AOC platform into clinical proof-of-concept, prioritizing genetic Alzheimer’s/Parkinson’s programs with data science enhancements for patient selection.[1][2] Trends like AI-accelerated precision medicine, expanded brain delivery tech, and global healthy aging demands will propel growth, potentially drawing pharma partnerships akin to founders’ prior $1B deals.[3][4] Its influence may evolve from seed-stage innovator to CNS RNAi leader, preserving cognitive health as lifespans extend—echoing its mission to silence harmful genes and protect minds.[2][4]
Aerska has raised $60.0M across 2 funding rounds. Most recently, it raised $39.0M Series A in February 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 9, 2026 | $39.0M Series A | age1, LSP Dementia Fund | Iaso Ventures |
| Sep 1, 2025 | $21.0M Seed | Backed VC, Seed Club Ventures |